Background
Gut microbiota, known as a complex ecological community colonized in human gastrointestinal (GI) tract, can interact with host factors to affect normal physiology and diseases [
1]. Healthy gut microbiota contributes to the metabolism of nutrition and drugs, structural integrity of intestinal mucosal barrier, immune regulation, and inhibition of pathogens [
2,
3]. Gut microbiota in the disordered state is likely to trigger many diseases, such as diarrhea [
4], inflammatory bowel disease [
5], metabolism disturbances (obesity, insulin resistance and diabetes) [
6], and cardiovascular diseases [
7]. Due to its ubiquitous roles in the maintenance of gut homeostasis and human health, gut microbiota exhibits great effects on the development and progression of diseases [
8,
9].
Among the diseases related to altered gut microbiota, chemotherapy-induced diarrhea (CID) is one of the most common digestive complications in cancer patients treated with chemotherapeutic drugs such as fluoropyrimidines and irinotecan [
10]. CID has been found to occur in 50–80% of cancer patients, especially those with advanced cancer [
11]. In addition, severe diarrhea (grade 3/4) was reported in 16.6% colorectal cancer patients receiving 5-fluorouracil (5-FU), the first-line chemotherapeutic drug for colorectal cancer [
12]. A growing number of evidences showed that CID could directly threaten the lives of patients, or indirectly affect the cycle and efficacy of chemotherapy [
13]. Therefore, at present, medication is being introduced into the treatment of CID. Modern medicines such as loperamide and octreotide are often used to relieve CID in clinical practices [
14]. However, their therapeutic effects are not satisfactory sometimes. For example, loperamide cannot alleviate several diarrheal features including abdominal cramps, an inability to eat, increasing fatigue, increasing weakness, chest pain, gastrointestinal bleeding [
15]. Long-acting octreotide acetate was not effective in preventing or relieving diarrhea in cancer patients undergoing chemoradiation therapy [
16]. In a word, there is still a lack of safe and effective modern medicines for the prevention and treatment of CID. Therefore, considerable attentions have been paid to complementary or alternative medicines such as traditional herbal medicines [
17,
18].
Shenzhu Capsule (SZC), a formula of Chinese herbal medicine, is composed of ginsenosides and polysaccharides from Renshen (rhizomes of
Panax ginseng C. A. Mey.), essential oil and polysaccharides from Baizhu (rhizomes of
Atractylodes macrocephala Koidz.). In the past few years, our researches mainly focused on the therapeutic effects of SZC for gastrointestinal diseases. For example, we had reported that SZC induced apoptosis of gastric cancer cells through mitochondrial pathway [
19‐
21]. In addition, SZC could reversely regulate the expression of some genes (metabolic, ion channels and transport proteins) in SGC-7901 tumor-bearing mice, resulting in the improvement of gastric cancer through multiple targets [
22]. Moreover, SZC not only regulated immune and inflammatory responses during the treatment of ulcerative colitis (UC), but also acted on UC complications (bloody diarrhea) and prevented UC from developing into colorectal cancer [
23]. At present, our attentions are being paid to investigate whether SZC exhibits therapeutic effect on CID, the GI side effect of chemotherapeutic drugs. As is known, many Chinese traditional anti-diarrheal formulae such as Shenling Baizhu Powder, Buzhong Yiqi Decoction and Sijunzi Decoction, all of which contain Renshen and Baizhu, had been proved to possess the ability of alleviating CID [
24‐
26]. However, no study has determined if SZC (the form of compatibility of Renshen and Baizhu) exerts any therapeutic effect on CID. In recent years, gut microbiota has become an important frontier to reveal the therapeutic mechanisms of medicines [
27]. Therefore, it is of great significance to investigate the therapeutic effect of SZC on CID based on gut microbiota.
In this study, we simulated a CID model in mice receiving 5-FU chemotherapy to evaluate the efficacy and interpret the potential mechanism of SZC in the treatment of diarrhea. Both diarrhea rates and histological changes of colonic tissues were recorded. 16S rDNA Amplicon Sequencing was used to analyze the gut microbial structure from fecal samples.
Methods
Chemicals and reagents
5-FU injection (25 mg/mL, No. 1708061) was provided by Tianjin JinYao Pharmaceutical Co., Ltd. (Tianjin, China). Standard compounds (purity > 98%) of ginsenosides Rg1, Rc, Rd, Re, Rb1, Rb2 and Rf were purchased from Chengdu Must Bio-Technology Co. Ltd. (Chengdu, China). Other chemicals and reagents were obtained from commercial sources.
Experimental animals
Twenty-four, 8-week-old SPF graded Kunming mice (12 males and 12 females) (Chengdu Dossy Experimental Animal Co., LTD., Chengdu, China, No. SCXK (chuan) 014–028) were adapted to the laboratory environment for 3 days before the experiment. The mice were housed under the standard environment (temperature of 25 ± 2 °C, humidity of 50 ± 5%, and a 12 h light/12 h dark cycle) with free access to the same water and diets. All efforts were made to minimize animal suffering. All experimental procedures involving animals were agreed by Animal Ethics Committee (Approval No. AEC-201706) in Chengdu University of Traditional Chinese Medicine (CDUTCM) (Chengdu, China).
Collection of Renshen and Baizhu
The materials were purchased from Lotus Pond Chinese herbal medicine market, Chengdu, Sichuan Province, People’s Republic of China. They were respectively identified as the rhizomes of Panax ginseng C. A. Mey. and Atractylodes macrocephala Koidz. by Associate Professor Lu Chen from School of Pharmacy in CDUTCM. The voucher specimens of Renshen and Baizhu (No. 17102101 and 17102102, respectively) were deposited at School of Pharmacy in CDUTCM.
Preparation and characterization of SZC
SZC is composed of ginsenosides and polysaccharides isolated from Renshen, essential oil and polysaccharides isolated from Baizhu. In this study, we extracted and characterized those components according to the preparing process of SZC [
24].
Renshen powder (200 g) was refluxed 3 times by 60% ethanol (8 ×) for total 6 h. Then, the combined extracts were concentrated by vacuum-rotary evaporation. The concentrate was eluted by 70% ethanol on D101 macroporous adsorptive resin. All the collected eluents were concentrated, and then dried at 40 °C in a vacuum oven. Final residue of ginsenosides (1.4 mg) was dissolved in 1 mL methanol and then filtered through a 0.45 μm filter membrane. Ginsenosides were characterized by HPLC (1260, Agilent, USA) with a C18 column (250 mm × 4.6 mm i.d., particle size 5 μm) (Cosmosil, Japan). The column was eluted at 35 °C with a detection wavelength at 203 nm and an injection volume of 10 μL. The flow rate of the mobile phase of water (A) and acetonitrile (B) was set at 1.0 mL/min. Gradient separation was based on the following: 0–10 min, 18–21% B; 10–20 min, 21–22% B; 20–30 min, 22–26% B; 30–40 min, 26–30% B; 40–55 min, 30–32% B; 55–75 min, 32–33.8% B; 75–90 min, 33.8–38% B; 90–105 min, 38–45% B; 105–110 min, 45–18% B. And the standard curves were obtained based on the absorbencies of different concentrations of standard ginsenosides Rg1, Re, Rf, Rc, Rd, Rb1 and Rb2.
Preparation and gas chromatography-mass spectrometer (GC-MS) characterization of essential oil from Baizhu in SZC
Baizhu powder (200 g) was refluxed by distilled water (10 ×) for 12 h. Final essential oil was gathered by steam distillation from the powder. Essential oil was characterized by GC-MS (GC 7890A and MS 5975C, Agilent, USA). Chromatographic separation was achieved on a capillary column HP-5MS (30 m × 0.25 mm i.d.; film thickness 0.25 μm). The electron ionization system operated at 70 eV of ionization energy. Helium was used as the carrier gas. 1 μL sample (essential oil: n-hexane, 1: 100 dilution) was injected and the injector temperature was set at 230.0 °C. Initial oven temperature was set at 100.0 °C, then increased to 120.0 °C at the rate of 3.0 °C/min and held at 120.0 °C for 20 min, and finally increased to 220.0 °C at the rate of 3.0 °C/min. MS was recorded in the range of 35–550 m/z at the rate of 1.0 scan/s. Identification of different components in essential oil was based on the comparison with the known constituents that stored in National Institute of Standards and Technology Library (NIST14.0).
Preparation and infrared spectroscopy (IR) characterization of polysaccharides from Renshen and Baizhu in SZC
Renshen (200 g) or Baizhu (200 g) powder was refluxed by distilled water (10 ×) for 2 h. The procedure was repeated 3 times. Then these extracted solutions were combined, concentrated, and cooled (4 °C) for 12 h. The cooled concentrate solution was precipitated in 60% ethanol, and final residues were dried at 40 °C in a vacuum oven. The characterization was carried out on a FTIR Spectrum (cary 660, Agilent, USA). Polysaccharides (1 mg) from Renshen or Baizhu were mixed with 150 mg KBr and homogenized by a pestle in the mortar. The mixture was then made by a hydraulic press into a slice, which was analyzed in IR at the wavenumber region from 400 to 4000 cm− 1.
Experimental design
According to the clinical dosages of Renshen (3 g per time) and Baizhu (3 g per time) (two Chinese medicines in SZC) in China Phannacopeia [
22,
28,
29], we chose the oral doses of ginsenosides and polysaccharides from Renshen as 126.7 mg/kg/d and 176.3 mg/kg/d respectively, and the oral doses of essential oil and polysaccharides from Baizhu as 35.3 μL/kg/d and 192.3 mg/kg/d respectively for mice. SZC was mixed in 0.1% sodium carboxymethyl cellulose solution. Twenty-four mice were randomly assigned into three groups (
n = 8): the control, model and SZC groups, with 4 males and 4 females per group. Our modeling method was based on the existing literature [
30]. The mice were orally administrated with SZC in a preventive mode on the first 2 days of the experiment, and then intraperitoneally injected with 5-FU (40 mg/kg/d) for 6 days. Mice in the SZC group were orally administrated with SZC half an hour before 5-FU chemotherapy. SZC treatment lasted until the 3rd day after the end of 5-FU chemotherapy. Mice in the control group received equal volume of liquid solvent for the whole 11 days, while the untreated mice in the model group received 5-FU chemotherapy on the 3–8 days.
Both body weights and diarrhea states were recorded every day. For the diarrhea evaluation, the mice with moist and unformed stools, or perianal stains, were deemed to show the clinical symptoms of diarrhea. The calculation formula of diarrhea rates in each group was given as follow: the diarrhea rate (%) = the number of diarrheal mice/the number of mice × 100%. Twenty-four hours after the last administration, fecal sample (4 g) was collected in sterile plastic tube and stored at − 80 °C. All the animals were sacrificed by cervical dislocation. Then thymuses and spleens were removed after the sacrifice of mice. Thymus and spleen indexes of each mouse were calculated according to the following formula: thymus (spleen) index = thymus (spleen) weight/body weight (mg/g).
Histological observation
The colon segments (2 cm) of each mouse were collected and fixed in 4% formaldehyde solution after the sacrifice of mice. Then the colonic samples were embedded by paraffin, sliced (4 μm), and stained with hematoxylin-eosin (HE). The histological changes of colonic segments were observed with the microscope (DMI300B, Leica, Germany).
Gut microbiota analysis
The genomic DNA of fecal samples was extracted by sodium dodecyl sulfate (SDS). After that, the concentration of DNA was detected using agarose gel electrophoresis. The V3–V4 region of bacterial 16S rRNA gene was amplified by polymerase chain reaction (PCR) with 341F–806R primer set. All PCR reactions were induced by High-Fidelity PCR Master Mix (New England Biolabs, USA). PCR products were detected by electrophoresis with 2% agarose gel, and then purified by Qiagen Gel Extraction Kit (Qiagen, Germany). TruSeq® DNA PCR-Free Sample Preparation Kit (Illumina, USA) was used to generate sequencing library. Library quality was evaluated on Qubit@2.0 Fluorometer (Thermo Scientific, USA) and Agilent Bioanalyzer 2100 system. Finally, the Library was conducted on Illumina HiSeq 2500 platform (Novogene, Beijing, China).
Paired-end reads of each sample were merged by FLASH (Version 1.2.7) to get raw tags. High-quality clean tags were generated from the strict filtration of raw tags by QIIME (Version 1.9.1). Final effective tags were produced after the removal of chimera sequences in the tags, which were detected by gold database (Version 1.9.1) and UCHIME Algorithm. The sequences at 97% identity were clustered into the same operational taxonomic units (OTUs) by Uparse (Version 7.0.1001). Then the representative sequence of each OTU was selected for the species annotation. MUSCLE (Version 3.8.31) was used for the multiple sequence alignments to get the phylogenetic relationships. The OTUs abundance information was normalized by the sequence number standard. ACE and Shannon indexes that respectively indicated richness and diversity of gut microbiota were calculated on QIIME (Version 1.7.0). Linear discriminant analysis effect size (LEfSe) was used to detect the dominant bacterial community difference among groups. The lowest screening value of linear discriminant analysis (LDA) in LEfSe software was defaulted to 4. Venn, LEfSe and Non-Metric Multi-Dimensional Scaling (NMDS) diagrams were built on R software (Version 2.15.3). Unweighted Pair-group Method with Arithmetic Means (UPGMA) Clustering was performed on QIIME software (Version 1.7.0).
Statistical analysis
Statistical analysis was performed on SPSS (Version 21). Data were presented as means ± Standard Error of Mean (SEM). One-way analysis of variance (ANOVA) followed by Least Significant Difference (LSD) test was used to analyze the statistical differences between multiple groups. Kruskal-Wallis test was applied if the data did not meet the assumptions of ANOVA. A value of P < 0.05 was considered statistically significant.
Discussion
In this study, all the model mice showed the clinical symptoms of diarrhea. We also found that thymus and spleen indexes in the model mice decreased significantly compared with those of the control group. Thymus and spleen indexes, whose levels depend on the extent of lymphocyte proliferation, can be used to partly reflect host immune function [
31]. The results indicated that the immune system of the model group was affected by 5-Fu chemotherapy. In addition, some histological changes of colonic sections were observed in model mice. Especially, the numbers of goblet cells in the model group were remarkably lower than those of the control group. Goblet cells play important roles in producing and maintaining protective mucus blankets by synthesization and secretion of high molecular weight glycoprotein such as mucin. The reduction of goblet cell number could directly or indirectly impact intestinal health [
32]. However, diarrhea and intestinal histological changes (Fig.
2) were significantly alleviated by SZC, which indicated that SZC was effective in the treatment of CID. More importantly, the potential mechanism behind this anti-diarrheal effect of SZC needed to be investigated in this study.
Previous studies have demonstrated that the pharmacological effects of Renshen and Baizhu were closely associated with gut microbiota. Renshen could effectively reduce body weight and change gut microbial composition in obese middle-aged Korean women [
33]. And Baizhu was capable of reducing intestinal pH value, improving the adhesion of
Bacillusbifidus, and fostering the normal gut microbiota in lincomycin-induced mice [
34]. Therefore, SZC, a formula composed of active herbal extracts from Renshen and Baizhu, might exert potentially modulatory effects on gut microbiota. In addition, gut microbiota is a contributing factor of many diseases including diarrhea [
35]. Therefore, we further analyzed gut microbiota from the feces of CID mice.
Gut microbial composition in fecal samples was determined by 16S rDNA Amplicon Sequencing. Species accumulation boxplot indicated that the species richness of gut microbiota was sufficient and stable for the following analyses when the total number of samples was 15 (
n = 5 in each group) (Fig.
4a). As shown in Fig.
4d and e, gut microbial richness and diversity were significantly increased in the model group. In general, the richness and diversity of microbial populations should be reduced under a pathological condition. The possible cause behind our results was that the richness and diversity of original microbiota was not reduced, and some potential pathogenic bacteria was introduced or increased in CID mice. Our results also showed that microbial richness and diversity decreased to normal levels after SZC treatment. Furthermore, the remarkable differences of distance existed among the three groups in NMDS plot, but a shorter distance was presented between the control and SZC groups. UPGMA clustering showed no obvious structural shift between the SZC and control groups, whereas the gut microbiota in the model group significantly deviated from that of the control group. Taken together, these results demonstrated the overall structure of gut microbiota in CID mice could be reversed to normal by SZC treatment.
Redundancy information uncovered the structural changes in the key phylotypes of gut microbiota based on the following classification: phylum, family and genus. Statistical results revealed that the abundances of
Firmicutes and
Proteobacteria significantly changed in the model group. But there was no difference between the SZC and control groups in the abundances of
Firmicutes and
Proteobacteria. Also, mice in the model group significantly increased the abundances of some genera such as
Clostridiumm,
Bacteroides,
Parabacteroides,
Alloprevotella,
Desulfovibrio,
Acinetobacter and
Pseudomonas, which might provide opportunities for the occurrence of diarrhea. For example, high-abundant
clostridium belonging to
Firmicutes is one of the causes of diarrhea [
36].
Bacteroides (
Bacteroidaceae family and
Bacteroidetes phylum), a complex organism colonized in the gut, may be the key factor influencing the integrity and immune development of intestinal mucosa in the process of diarrhea. Increased
Bacteroides may also induce inflammation or even carcinogenesis [
37,
38].
Parabacteroides in high abundance was found in immune-related diarrhea [
39]. In addition,
Alloprevotella (
Prevotellaceae family) is an anaerobic Gram-negative bacilli with the high relative abundance in patients with inflammatory bowel disease (IBD) [
40]. Both
Desulfovibrio and
Acinetobacter (
Proteobacteria family) were associated with bloody diarrhea [
41,
42].
Pseudomonas is commonly found in patients with malnourished and infectious diarrhea [
43,
44]. These above studies indicated that the growth of these genera (potential pathogens) was associated with diarrhea. As shown in Fig.
6, SZC treatment reduced the abundances of these genera in CID mice. Therefore, our results suggested that SZC could inhibit the growth of potential pathogens and modulated microbial structure in the feces. Moreover,
Lactobacillus is an important genus for relieving diarrhea [
45]. On the contrary, no significant difference in the abundances of
Lactobacillus (probiotic) existed among the three groups, which was not in accordance with the results of 5-FU-induced decrease of
Lactobacillus in the previous study [
46]. The reason behind the difference might be that our results were based on fecal microbiota in mice, while the previous study focused on fecal microbiota in rats. Therefore, the relationship between
Lactobacillus and CID still needs a deeper investigation. Conclusively, these results suggested that amelioration of CID with SZC treatment might be mainly mediated by inhibition of potential pathogens.
Although SZC could modulate gut microbial structure of fecal samples in CID mice, the specific relationship between the anti-diarrheal activity of SZC and gut microbiota remained undefined. For example, fecal collection in a non-invasive manner was chosen as the sampling method for gut microbial analysis. However, fecal communities may not completely represent bacterial communities living in intestines, although they play an important role in maintaining intestinal homeostasis and microbial diversity [
47,
48]. In addition to structural modulation of gut microbiota, the therapeutic effects of herbal drugs could also be influenced by gut microbial metabolism and pharmacokinetics [
49]. Therefore, there is still no systematic and comprehensive interpretation for the association between the anti-diarrheal effect of SZC and gut microbiota, which will be our focus in the future researches.
Conclusion
In conclusion, our study found that gut microbial structure was modulated by SZC (the Chinese herbal formula) during the alleviation of CID. Especially, at genus level, SZC significantly inhibited the growth of potential pathogens closely related to diarrhea, including Clostridiumm, Bacteroides, Parabacteroides, Alloprevotella, Acinetobacter and Pseudomonas. These results indicated that gut microbial modulation was associated with the anti-diarrheal activity of SZC.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.